Topical Estrogen: Brief Intervention to Improve Postoperative Experience for Transgender Men Undergoing Hysterectomy
Women and Infants Hospital of Rhode Island
48 participants
May 1, 2025
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to determine if applying a single dose of topical estrogen cream in the operating room at the end of your hysterectomy (removal of uterus and cervix) improves the postoperative experience with bleeding and potential symptoms of dysphoria (a feeling of discomfort or distress). Topical estrogen cream is sometimes used if patients have increased risk of bleeding with surgery but is not currently utilized in a consistent way. This study aims to answer the question of whether this is a helpful treatment and should be included in standard postoperative care.
Eligibility
Inclusion Criteria8
- Gender diverse/transgender men
- Age 18 or older
- Have been on testosterone for at least 6 months with plan to undergo gender-affirming hysterectomy and are willing to be randomized to the use of topical estrogen postoperatively.
- Have stable physical and mental health
- No contraindications to estrogen therapy
- Must be proficient in English or Spanish
- Must have access to a device to receive text messages for study follow up
- Must agree to allow their medical data to be used for research purposes
Exclusion Criteria3
- Under age 18
- Have not been on testosterone for at least 6 months prior to planned hysterectomy
- Known allergy to topical estrogen
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The investigators will conduct a double blinded randomized control pilot trial. Participants will be randomized in 1:1 fashion to either receive no treatment or receive 2g of estradiol cream, placed after clearing the vaginal vault of any blood and discharge, at the conclusion of the surgery.
This arm will not receive estradiol or other cream
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06969326